Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

September 21, 2018September 21, 2018

FDA Approves Subcutaneous Form of Actemra for Active Systemic Juvenile Idiopathic Arthritis

News

The U.S. Food and Drug Administration (FDA) has approved Genentech’s formulation of Actemra (tocilizumab) by subcutaneous injection for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 and older. ... Read more

May 4, 2018May 4, 2018

Patient-Centered Outcomes Research Institute Approves $20 Million in New Research Funding

News

The Patient-Centered Outcomes Research Institute’s (PCORI) board of governors has approved more than $20 million in research funding to support four projects in various fields, including arthritis, irritable bowel disease, depression, ... Read more

April 2, 2018April 2, 2018

UK-wide CLUSTER Consortium Aimed at Juvenile Arthritis and Uveitis Research Receives Funding

News

The CLUSTER consortium, a U.K-wide research effort focused on improving the lives of young people with juvenile idiopathic arthritis (JIA) and uveitis, was recently awarded £5 million (about $7 million USD). ... Read more

March 7, 2018March 7, 2018

RCGD 423 Therapy May Help Avoid Joint Replacements in JA, Other Conditions

News

Researchers have identified a compound that promotes cartilage repair and may be used to treat juvenile arthritis, avoiding the need for joint replacement. The compound, called the Regulator of Cartilage ... Read more

February 28, 2018February 28, 2018

Higher Risk of Cancer in JA Patients Not Associated with TNF Inhibitors, Study Finds

News

While a diagnosis of juvenile idiopathic arthritis, pediatric inflammatory bowel disease, or pediatric plaque psoriasis increases the risk of cancer, use of TNF inhibitors do not seem to significantly affect malignancy ... Read more

November 3, 2017November 3, 2017

Momenta and Mylan’s Biosimilar Candidate M834 Misses Initial Trial Goals

News

Momenta Pharmaceuticals and Mylan recently reported that M834, a biosimilar candidate for abatacept designed to treat autoimmune diseases, did not meet its primary pharmacokinetic (PK) goals in a direct comparison study with Orencia ... Read more

November 1, 2017November 1, 2017

Higher Rate of Infections in JIA Patients Who Take Biologic Therapies, Study Finds

News

Patients with juvenile idiopathic arthritis (JIA) who take biologic therapies have a higher rate of serious or opportunistic infections, a new study shows. The study reporting that finding, “High rate ... Read more

August 23, 2017August 23, 2017

Europe’s CHMP Green-lights AbbVie’s Humira for Pediatric Anterior Uveitis

News

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion to Abbvie‘s Humira (adalimumab) for the treatment of chronic ... Read more